CL2021002099A1 - Combinación farmacéutica que comprende tno155 y ribociclib. - Google Patents
Combinación farmacéutica que comprende tno155 y ribociclib.Info
- Publication number
- CL2021002099A1 CL2021002099A1 CL2021002099A CL2021002099A CL2021002099A1 CL 2021002099 A1 CL2021002099 A1 CL 2021002099A1 CL 2021002099 A CL2021002099 A CL 2021002099A CL 2021002099 A CL2021002099 A CL 2021002099A CL 2021002099 A1 CL2021002099 A1 CL 2021002099A1
- Authority
- CL
- Chile
- Prior art keywords
- tno155
- ribociclib
- pharmaceutical combination
- treatment
- compositions
- Prior art date
Links
- UCJZOKGUEJUNIO-IINYFYTJSA-N (3S,4S)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound C[C@@H]1OCC2(CCN(CC2)C2=CN=C(SC3=C(Cl)C(N)=NC=C3)C(N)=N2)[C@@H]1N UCJZOKGUEJUNIO-IINYFYTJSA-N 0.000 title abstract 2
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 title abstract 2
- 229950003687 ribociclib Drugs 0.000 title abstract 2
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940125811 TNO155 Drugs 0.000 abstract 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 abstract 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962804708P | 2019-02-12 | 2019-02-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021002099A1 true CL2021002099A1 (es) | 2022-04-18 |
Family
ID=69724013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021002099A CL2021002099A1 (es) | 2019-02-12 | 2021-08-10 | Combinación farmacéutica que comprende tno155 y ribociclib. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12343344B2 (enExample) |
| EP (1) | EP3923941B1 (enExample) |
| JP (1) | JP7493521B2 (enExample) |
| KR (1) | KR20210126653A (enExample) |
| CN (1) | CN113382731A (enExample) |
| AU (3) | AU2020222296B2 (enExample) |
| BR (1) | BR112021015632A2 (enExample) |
| CA (1) | CA3127286A1 (enExample) |
| CL (1) | CL2021002099A1 (enExample) |
| IL (1) | IL284835B2 (enExample) |
| MX (1) | MX2021009563A (enExample) |
| TW (1) | TWI831916B (enExample) |
| WO (1) | WO2020165734A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120208856A (zh) | 2018-09-29 | 2025-06-27 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物的制造 |
| US12138262B2 (en) | 2018-09-29 | 2024-11-12 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of SHP2, as well as products resulting from acid addition |
| WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| US20220160706A1 (en) * | 2019-02-12 | 2022-05-26 | Novartis Ag | Pharmaceutical combination comprising tno155 and a pd-1 inhibitor |
| AU2021293228A1 (en) | 2020-06-18 | 2023-02-09 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors |
| KR20230038197A (ko) | 2020-07-08 | 2023-03-17 | 노파르티스 아게 | Shp2의 활성 억제를 위한 화합물 및 조성물의 제조 |
| US20250195521A1 (en) | 2020-09-03 | 2025-06-19 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| EP4334324A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| US20240238284A1 (en) * | 2021-05-05 | 2024-07-18 | Novartis Ag | Compounds and compositions for the treatment of mpnst |
| WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| US12390469B2 (en) * | 2021-05-05 | 2025-08-19 | Huyabio International, Llc | SHP2 inhibitor monotherapy and uses thereof |
| TW202309052A (zh) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| US20240293422A1 (en) * | 2021-06-24 | 2024-09-05 | Erasca, Inc. | Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| TW202342040A (zh) | 2022-02-21 | 2023-11-01 | 瑞士商諾華公司 | 藥物配製物 |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| KR20250022133A (ko) | 2022-06-10 | 2025-02-14 | 레볼루션 메디슨즈, 인크. | 거대고리 ras 억제제 |
| WO2024115680A1 (en) | 2022-12-01 | 2024-06-06 | Krka, D.D., Novo Mesto | Ribociclib salts and formulations thereof |
| KR20240097396A (ko) | 2022-12-20 | 2024-06-27 | 재단법인대구경북과학기술원 | 리보시클립을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 |
| KR20250164828A (ko) | 2023-03-30 | 2025-11-25 | 레볼루션 메디슨즈, 인크. | Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도 |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| AU2024243852A1 (en) | 2023-04-07 | 2025-11-06 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| KR20250172857A (ko) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형 |
| KR20250169290A (ko) | 2023-04-14 | 2025-12-02 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형, 이를 함유하는 조성물 및 이의 사용 방법 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8685980B2 (en) | 2008-08-22 | 2014-04-01 | Novartis Ag | Pyrrolopyrimidine compounds and their uses |
| JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| JP7503380B2 (ja) * | 2017-01-10 | 2024-06-20 | ノバルティス アーゲー | Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬 |
| BR112020004246A2 (pt) * | 2017-09-07 | 2020-09-01 | Revolution Medicines, Inc. | composições inibidoras de shp2 e métodos para o tratamento de câncer |
| EP3897659A4 (en) | 2018-12-17 | 2022-09-07 | Lunella Biotech, Inc. | Triple combination therapies for anti-aging |
| AU2019403048B2 (en) | 2018-12-17 | 2025-01-23 | Lunella Biotech, Inc. | Triple combination therapies for targeting mitochondria and killing cancer stem cells |
| EP4249000A3 (en) | 2019-02-12 | 2023-12-27 | Novartis AG | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
| US20220160706A1 (en) | 2019-02-12 | 2022-05-26 | Novartis Ag | Pharmaceutical combination comprising tno155 and a pd-1 inhibitor |
-
2020
- 2020-02-10 CN CN202080012520.8A patent/CN113382731A/zh active Pending
- 2020-02-10 WO PCT/IB2020/051031 patent/WO2020165734A1/en not_active Ceased
- 2020-02-10 TW TW109104042A patent/TWI831916B/zh active
- 2020-02-10 BR BR112021015632-1A patent/BR112021015632A2/pt unknown
- 2020-02-10 IL IL284835A patent/IL284835B2/en unknown
- 2020-02-10 JP JP2021546211A patent/JP7493521B2/ja active Active
- 2020-02-10 KR KR1020217028654A patent/KR20210126653A/ko not_active Ceased
- 2020-02-10 MX MX2021009563A patent/MX2021009563A/es unknown
- 2020-02-10 EP EP20707827.0A patent/EP3923941B1/en active Active
- 2020-02-10 CA CA3127286A patent/CA3127286A1/en active Pending
- 2020-02-10 AU AU2020222296A patent/AU2020222296B2/en active Active
- 2020-02-10 US US17/430,219 patent/US12343344B2/en active Active
-
2021
- 2021-08-10 CL CL2021002099A patent/CL2021002099A1/es unknown
-
2023
- 2023-06-15 AU AU2023203751A patent/AU2023203751A1/en not_active Abandoned
-
2025
- 2025-05-23 AU AU2025203816A patent/AU2025203816A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3923941A1 (en) | 2021-12-22 |
| AU2020222296B2 (en) | 2023-04-06 |
| US12343344B2 (en) | 2025-07-01 |
| AU2020222296A1 (en) | 2021-08-05 |
| EP3923941B1 (en) | 2025-12-03 |
| CA3127286A1 (en) | 2020-08-20 |
| JP2022519375A (ja) | 2022-03-23 |
| AU2023203751A1 (en) | 2023-07-13 |
| IL284835B1 (en) | 2025-04-01 |
| AU2025203816A1 (en) | 2025-06-12 |
| JP7493521B2 (ja) | 2024-05-31 |
| WO2020165734A1 (en) | 2020-08-20 |
| BR112021015632A2 (pt) | 2021-10-05 |
| IL284835B2 (en) | 2025-08-01 |
| US20220160707A1 (en) | 2022-05-26 |
| MX2021009563A (es) | 2021-09-08 |
| KR20210126653A (ko) | 2021-10-20 |
| TWI831916B (zh) | 2024-02-11 |
| IL284835A (en) | 2021-08-31 |
| CN113382731A (zh) | 2021-09-10 |
| TW202045171A (zh) | 2020-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002099A1 (es) | Combinación farmacéutica que comprende tno155 y ribociclib. | |
| CL2021002100A1 (es) | Combinación farmacéutica que comprende tno155 y un inhibidor de pd–1. | |
| EP4249000A3 (en) | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor | |
| CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| MX2020012137A (es) | Inhibidores de mcl-1. | |
| CL2018002708A1 (es) | Métodos para la inhibición de la angiogénesis en un sujeto que lo necesita | |
| CO2019001212A2 (es) | Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos | |
| AR119934A1 (es) | Inhibidores de pikfyve para terapia contra el cáncer | |
| CR20190403A (es) | Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma | |
| CL2019000228A1 (es) | Tratamiento conjunto contra tipos de cáncer hematológico. | |
| CL2019002557A1 (es) | Pirimidopirimidinonas útiles como inhibidores de la quinasa wee-1. | |
| CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
| CO2019013047A2 (es) | Composiciones sólidas para administración oral | |
| ECSP20082339A (es) | Moduladores de la expresión de apol1 | |
| MX2021000516A (es) | Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5. | |
| BR112022022305A2 (pt) | Combinação farmacêutica que compreende tno155 e nazartinibe | |
| MX2018014938A (es) | Combinaciones farmaceuticas para el tratamiento del cancer. | |
| CO2020010013A2 (es) | Terapia de combinación para tratar o prevenir el cáncer | |
| CL2021000018A1 (es) | Oligonucleótidos para modular la expresión de rtel1 | |
| CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
| MX2023005829A (es) | Combinaciones farmaceuticas para tratar el cancer. | |
| CL2020002505A1 (es) | Una combinación farmacéutica triple que comprende dabrafenib, trametinib y un inhibidor de erk | |
| CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
| CL2020002347A1 (es) | Nuevo compuesto y composición farmacéutica que lo comprende | |
| MX2019005194A (es) | Combinaciones de inhibidores de fgfr4 y secuestrantes de acido biliar. |